Photo by campaign_creators from unsplash
Thrombotic thrombocytopenic purpura (TTP) is a rare disease with 90% mortality if untreated. Since the Canadian Apheresis Group (CAG) trial showed greater survival with therapeutic plasma exchange (TPE) versus plasma… Click to show full abstract
Thrombotic thrombocytopenic purpura (TTP) is a rare disease with 90% mortality if untreated. Since the Canadian Apheresis Group (CAG) trial showed greater survival with therapeutic plasma exchange (TPE) versus plasma infusion, there has been widespread adoption of TPE. Beyond TPE, there is significant practice variation. To characterize this, we developed a survey sent to physicians who might be directly involved in TTP management.
Keywords:
survey;
thrombotic thrombocytopenic;
practice;
thrombocytopenic purpura;
treat thrombotic
Journal Title: Journal of Clinical Apheresis
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Journal of Clinical Apheresis
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!